Indeed, flavopiridol blocks the growth of both multiple myeloma and chronic lymphocytic leukemia (CLL) cells, in which downregulation of Mcl-1, a Bcl-2 family member, was found to be flavopiridol’s primary mechanism of action. This evidence concerns the gene MCL1 and B-cell chronic lymphocytic leukemia.